Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01174264
Other study ID # NCI-2012-03099
Secondary ID NCI-2012-03099NC
Status Active, not recruiting
Phase Phase 1/Phase 2
First received July 30, 2010
Last updated March 6, 2017
Start date October 2009

Study information

Verified date October 2016
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized clinical trial studies the effect of food on the pharmacokinetics of vismodegib. Studying the effects of meals on the absorption of vismodegib may help doctors prescribe correct doses and label the drug accurately.


Description:

PRIMARY OBJECTIVES:

I. To evaluate the effect of prandial states on the pharmacokinetic parameters of GDC-0449 (vismodegib).

II. To evaluate the effect of fat content of meals on the pharmacokinetic parameters of GDC-0449.

SECONDARY OBJECTIVES:

I. To evaluate the effect of prandial states and fat content of meals on the safety profile of GDC-0449.

II. To describe any anticancer activities of GDC-0449.

OUTLINE: Patients are randomized to 1 of 3 treatment arms.

ARM I: Patients receive a single dose of vismodegib orally (PO) on an empty stomach. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.

ARM II: Patients receive a single dose of vismodegib PO after eating a high fat meal. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.

ARM III: Patients receive a single dose of vismodegib PO after eating a low fat meal. Beginning 7 days later, patients receive vismodegib PO after eating a meal daily on days 1-28.

In all arms, treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 63
Est. completion date
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed advanced malignancies (except for leukemias) refractory to standard of care therapy, or for whom no standard of care therapy is available

- Measurable or non-measurable disease

- An anticipated life expectancy > 3 months

- Karnofsky performance status of > 70%

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin within normal institutional limits

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal

- Creatinine =< 1.5 X institutional upper limit of normal

- Women of child-bearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

- Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 48 hours prior to the first dose of GDC-0449 (serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24-hour period prior to the administration of GDC-0449; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing GDC-0449, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient's understanding of the teratogenic potential of GDC-0449

- Female subjects of childbearing potential are defined as follows:

- Patients with regular menses

- Patients, after menarche with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding

- Women who have had tubal ligation

- Female subjects may be considered to NOT be of childbearing potential for the following reasons:

- The patient has undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy or bilateral oophorectomy

- The patient is medically confirmed to menopausal (no menstrual period) for 24 consecutive months

- Pre-pubertal females; the parent or guardian of young female patients who have not yet started menstruation should verify that menstruation has not begun; if a young female patient reaches menarche during the study, then she is to be considered as a woman of childbearing potential from that time forward

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier

- Patients may not be receiving any other investigational agents

- Patients with known brain metastases should be excluded from this clinical trial

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449 or other agents used in study

- Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsules

- Patients with clinically important history of liver disease, including viral or other hepatitis or cirrhosis are ineligible

- Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

- Patients with medical conditions that require the following medications will be excluded

- Strong inhibitors of cytochrome P450 3A4 (CYP3A4) (clarithromycin, itraconazole, ketoconazole, nefazodone, erythromycin, grapefruit juice, verapamil, and diltiazem)

- Strong inhibitors of cytochrome P450 2C9 (CYP2C9) (fluconazole and amiodarone)

- Inducers of CYP3A4 (carbamazepine, dexamethasone, modafinil, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort, troglitazone)

- Inducers of CYP2C9 (rifampin, and secobarbital)

- Patients who have a medical condition or dietary restrictions that prevent him or her from fasting for at least 10 hours (overnight) or eating a high calorie meal

- Any ambiguity in the inclusion/exclusion criteria should be clarified and resolved by communication with the study investigators

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pharmacological Study
Correlative studies
Drug:
Vismodegib
Given PO

Locations

Country Name City State
United States University of Chicago Comprehensive Cancer Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax Following Single Dose of Drug Highest observed concentration over the 168 hour period. Blood samples were collected at j0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 24, 48, 120, and 168 hours. 168 hours
Primary AUC Following Single Dose of Drug Area under the curve from 0-168 hours. 168 hours
Primary Tmax`Following Single Dose of Drug Time of maximum drug concentration 168 hours
Primary Tlag Following Single Dose of Drug Time between drug administration and when it is first observed in the systemic circulation. 168 hours
Primary Ctrough Following Steady State Exposure for 14 Days Minimum blood concentration over 24-hour observation period. Blood sample collected at 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 hours. 24 hours
Primary Cmax Following Steady State Exposure for 14 Days Maximum drug concentration over 24 hours. 24 hours
Primary AUC Following Steady State Exposure for 14 Days Area under the curve from 0 to 24 hours. 24 hours
Primary Tmax Following Steady State Exposure for 14 Days Time of maximum drug concentration. 24 hours
Secondary Objective Responses in Patients With Solid Tumors Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Up to 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Active, not recruiting NCT02243592 - Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Completed NCT03445572 - Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer N/A
Active, not recruiting NCT02860039 - High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Phase 2
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT01635413 - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial) N/A
Completed NCT00026169 - Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure Phase 1
Recruiting NCT04534075 - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial Phase 3
Active, not recruiting NCT01806129 - Reproductive Health Program in Patients With Cancer N/A
Recruiting NCT03915717 - Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
Recruiting NCT02280161 - Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
Recruiting NCT05520281 - Short-term Psychodynamic Psychotherapy in Serious Physical Illness N/A
Terminated NCT00532064 - Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
Completed NCT04990882 - FAPI PET/CT Prospective Interobserver Agreement
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05886764 - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials N/A
Completed NCT01432431 - Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff N/A
Completed NCT01506440 - Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy